21
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      SARS-CoV-2–related MIS-C: A key to the viral and genetic causes of Kawasaki disease?

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          SARS-CoV-2 is the trigger of MIS-C, which suggests that other viruses may trigger different forms of Kawasaki disease. The discovery of inborn errors of immunity underlying MIS-C would facilitate that of inborn errors of immunity to viruses underlying Kawasaki disease.

          Abstract

          Multisystem inflammatory syndrome in children (MIS-C) emerged in April 2020 in communities with high COVID-19 rates. This new condition is heterogenous but resembles Kawasaki disease (KD), a well-known but poorly understood and clinically heterogenous pediatric inflammatory condition for which weak associations have been found with a myriad of viral illnesses. Epidemiological data clearly indicate that SARS-CoV-2 is the trigger for MIS-C, which typically occurs about 1 mo after infection. These findings support the hypothesis of viral triggers for the various forms of classic KD. We further suggest that rare inborn errors of immunity (IEIs) altering the immune response to SARS-CoV-2 may underlie the pathogenesis of MIS-C in some children. The discovery of monogenic IEIs underlying MIS-C would shed light on its pathogenesis, paving the way for a new genetic approach to classic KD, revisited as a heterogeneous collection of IEIs to viruses.

          Related collections

          Most cited references163

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

          Abstract Objective To characterise the clinical features of patients admitted to hospital with coronavirus disease 2019 (covid-19) in the United Kingdom during the growth phase of the first wave of this outbreak who were enrolled in the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) World Health Organization (WHO) Clinical Characterisation Protocol UK (CCP-UK) study, and to explore risk factors associated with mortality in hospital. Design Prospective observational cohort study with rapid data gathering and near real time analysis. Setting 208 acute care hospitals in England, Wales, and Scotland between 6 February and 19 April 2020. A case report form developed by ISARIC and WHO was used to collect clinical data. A minimal follow-up time of two weeks (to 3 May 2020) allowed most patients to complete their hospital admission. Participants 20 133 hospital inpatients with covid-19. Main outcome measures Admission to critical care (high dependency unit or intensive care unit) and mortality in hospital. Results The median age of patients admitted to hospital with covid-19, or with a diagnosis of covid-19 made in hospital, was 73 years (interquartile range 58-82, range 0-104). More men were admitted than women (men 60%, n=12 068; women 40%, n=8065). The median duration of symptoms before admission was 4 days (interquartile range 1-8). The commonest comorbidities were chronic cardiac disease (31%, 5469/17 702), uncomplicated diabetes (21%, 3650/17 599), non-asthmatic chronic pulmonary disease (18%, 3128/17 634), and chronic kidney disease (16%, 2830/17 506); 23% (4161/18 525) had no reported major comorbidity. Overall, 41% (8199/20 133) of patients were discharged alive, 26% (5165/20 133) died, and 34% (6769/20 133) continued to receive care at the reporting date. 17% (3001/18 183) required admission to high dependency or intensive care units; of these, 28% (826/3001) were discharged alive, 32% (958/3001) died, and 41% (1217/3001) continued to receive care at the reporting date. Of those receiving mechanical ventilation, 17% (276/1658) were discharged alive, 37% (618/1658) died, and 46% (764/1658) remained in hospital. Increasing age, male sex, and comorbidities including chronic cardiac disease, non-asthmatic chronic pulmonary disease, chronic kidney disease, liver disease and obesity were associated with higher mortality in hospital. Conclusions ISARIC WHO CCP-UK is a large prospective cohort study of patients in hospital with covid-19. The study continues to enrol at the time of this report. In study participants, mortality was high, independent risk factors were increasing age, male sex, and chronic comorbidity, including obesity. This study has shown the importance of pandemic preparedness and the need to maintain readiness to launch research studies in response to outbreaks. Study registration ISRCTN66726260.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Autoantibodies against type I IFNs in patients with life-threatening COVID-19

            The genetics underlying severe COVID-19 The immune system is complex and involves many genes, including those that encode cytokines known as interferons (IFNs). Individuals that lack specific IFNs can be more susceptible to infectious diseases. Furthermore, the autoantibody system dampens IFN response to prevent damage from pathogen-induced inflammation. Two studies now examine the likelihood that genetics affects the risk of severe coronavirus disease 2019 (COVID-19) through components of this system (see the Perspective by Beck and Aksentijevich). Q. Zhang et al. used a candidate gene approach and identified patients with severe COVID-19 who have mutations in genes involved in the regulation of type I and III IFN immunity. They found enrichment of these genes in patients and conclude that genetics may determine the clinical course of the infection. Bastard et al. identified individuals with high titers of neutralizing autoantibodies against type I IFN-α2 and IFN-ω in about 10% of patients with severe COVID-19 pneumonia. These autoantibodies were not found either in infected people who were asymptomatic or had milder phenotype or in healthy individuals. Together, these studies identify a means by which individuals at highest risk of life-threatening COVID-19 can be identified. Science, this issue p. eabd4570, p. eabd4585; see also p. 404
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

              Abstract Background Understanding the epidemiology and clinical course of multisystem inflammatory syndrome in children (MIS-C) and its temporal association with coronavirus disease 2019 (Covid-19) is important, given the clinical and public health implications of the syndrome. Methods We conducted targeted surveillance for MIS-C from March 15 to May 20, 2020, in pediatric health centers across the United States. The case definition included six criteria: serious illness leading to hospitalization, an age of less than 21 years, fever that lasted for at least 24 hours, laboratory evidence of inflammation, multisystem organ involvement, and evidence of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on reverse-transcriptase polymerase chain reaction (RT-PCR), antibody testing, or exposure to persons with Covid-19 in the past month. Clinicians abstracted the data onto standardized forms. Results We report on 186 patients with MIS-C in 26 states. The median age was 8.3 years, 115 patients (62%) were male, 135 (73%) had previously been healthy, 131 (70%) were positive for SARS-CoV-2 by RT-PCR or antibody testing, and 164 (88%) were hospitalized after April 16, 2020. Organ-system involvement included the gastrointestinal system in 171 patients (92%), cardiovascular in 149 (80%), hematologic in 142 (76%), mucocutaneous in 137 (74%), and respiratory in 131 (70%). The median duration of hospitalization was 7 days (interquartile range, 4 to 10); 148 patients (80%) received intensive care, 37 (20%) received mechanical ventilation, 90 (48%) received vasoactive support, and 4 (2%) died. Coronary-artery aneurysms (z scores ≥2.5) were documented in 15 patients (8%), and Kawasaki’s disease–like features were documented in 74 (40%). Most patients (171 [92%]) had elevations in at least four biomarkers indicating inflammation. The use of immunomodulating therapies was common: intravenous immune globulin was used in 144 (77%), glucocorticoids in 91 (49%), and interleukin-6 or 1RA inhibitors in 38 (20%). Conclusions Multisystem inflammatory syndrome in children associated with SARS-CoV-2 led to serious and life-threatening illness in previously healthy children and adolescents. (Funded by the Centers for Disease Control and Prevention.)
                Bookmark

                Author and article information

                Contributors
                Role: ConceptualizationRole: Writing - original draftRole: Writing - review & editing
                Role: ConceptualizationRole: SupervisionRole: Writing - original draftRole: Writing - review & editing
                Role: Data curationRole: Writing - original draftRole: Writing - review & editing
                Role: InvestigationRole: VisualizationRole: Writing - original draftRole: Writing - review & editing
                Role: ConceptualizationRole: Data curationRole: Formal analysisRole: InvestigationRole: ValidationRole: VisualizationRole: Writing - original draftRole: Writing - review & editing
                Role: ConceptualizationRole: VisualizationRole: Writing - review & editing
                Role: Writing - original draftRole: Writing - review & editing
                Role: ConceptualizationRole: Writing - review & editing
                Role: Writing - original draftRole: Writing - review & editing
                Role: Writing - original draftRole: Writing - review & editing
                Role: Writing - original draftRole: Writing - review & editing
                Role: ConceptualizationRole: Writing - original draftRole: Writing - review & editing
                Role: ConceptualizationRole: Funding acquisitionRole: Writing - original draftRole: Writing - review & editing
                Role: Funding acquisitionRole: SupervisionRole: Writing - review & editing
                Role: ConceptualizationRole: Data curationRole: Funding acquisitionRole: Writing - original draftRole: Writing - review & editing
                Journal
                J Exp Med
                J Exp Med
                jem
                The Journal of Experimental Medicine
                Rockefeller University Press
                0022-1007
                1540-9538
                07 June 2021
                27 April 2021
                27 April 2021
                : 218
                : 6
                : e20210446
                Affiliations
                [1 ]Department of Paediatric Infectious Diseases and Virology, Imperial College London, London, UK
                [2 ]Centre for Paediatrics and Child Health, Faculty of Medicine, Imperial College London, London, UK
                [3 ]Science for Life Laboratory, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
                [4 ]St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY
                [5 ]Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale, Necker Hospital for Sick Children, Paris, France
                [6 ]University of Paris, Imagine Institute, Paris, France
                [7 ]Department of Pediatrics, University of British Columbia, Vancouver, Canada
                [8 ]British Columbia Children’s Hospital Research Institute, Vancouver, Canada
                [9 ]Department of General Pediatrics and Pediatric Infectious Diseases, Necker Hospital for Sick Children, Assistance Publique - Hôpitaux de Paris, University of Paris, Paris, France
                [10 ]Pasteur Institute, Biodiversity and Epidemiology of Bacterial Pathogens, Paris, France
                [11 ]Department of Immunobiology, Yale University School of Medicine, New Haven, CT
                [12 ]Division of Allergy Immunology, Children’s Hospital of Philadelphia, Philadelphia, PA
                [13 ]Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
                [14 ]Centre International de Recherche en Infectiologie, University of Lyon, Institut National de la Santé et de la Recherche Médicale, U1111, Université Claude Bernard, Lyon 1, Le Centre National de la Recherche Scientifique, UMR5308, Lyon, France
                [15 ]National Reference Center for Rheumatic, Autoimmune and Systemic Diseases in Children (RAISE), Pediatric Nephrology, Rheumatology, Dermatology Unit, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France
                [16 ]Garvan Institute of Medical Research, Darlinghurst, Australia
                [17 ]St. Vincent’s Clinical School, Faculty of Medicine, University of New South Wales Sydney, Sydney, Australia
                [18 ]Department of Pediatrics, Columbia University Irving Medical Center, New York, NY
                [19 ]Center for Inborn Errors of Immunity, Precision Immunology Institute, Mindich Child Health and Development Institute, Department of Microbiology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY
                [20 ]Howard Hughes Medical Institute, New York, NY
                [21 ]Multisystem Inflammatory Syndrome in Children, COVID Human Genetic Effort
                Author notes
                Correspondence to Shen-Ying Zhang: shzh289@ 123456rockefeller.edu

                Disclosures: The authors declare no competing interests exist.

                All authors contributed equally to this paper.

                Members of MIS-C@CHGE are listed at the end of the PDF.

                Author information
                https://orcid.org/0000-0002-3519-0727
                https://orcid.org/0000-0002-8103-0046
                https://orcid.org/0000-0001-7209-6257
                https://orcid.org/0000-0002-4363-2660
                https://orcid.org/0000-0001-9561-669X
                https://orcid.org/0000-0002-5754-0820
                https://orcid.org/0000-0001-5569-4132
                https://orcid.org/0000-0003-4902-5332
                https://orcid.org/0000-0002-5360-5180
                https://orcid.org/0000-0002-3913-3869
                https://orcid.org/0000-0003-2767-6919
                https://orcid.org/0000-0001-7016-6493
                https://orcid.org/0000-0002-9277-3232
                https://orcid.org/0000-0002-7782-4169
                https://orcid.org/0000-0002-9449-3672
                Article
                jem.20210446
                10.1084/jem.20210446
                8080850
                33904890
                d924822e-64a8-47eb-a9ec-bd8b58f642fa
                © 2021 Sancho-Shimizu et al.

                This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

                History
                : 22 February 2021
                : 24 March 2021
                : 07 April 2021
                Page count
                Pages: 16
                Funding
                Funded by: Howard Hughes Medical Institute, DOI http://dx.doi.org/10.13039/100000011;
                Funded by: Rockefeller University, DOI http://dx.doi.org/10.13039/100012007;
                Funded by: St. Giles Foundation, DOI http://dx.doi.org/10.13039/100002350;
                Funded by: National Institutes of Health, DOI http://dx.doi.org/10.13039/100000002;
                Award ID: R01AI088364
                Award ID: R01AI148963
                Award ID: R01AI151029
                Award ID: R01AI150300
                Award ID: K08AI135091
                Award ID: R21AI144315-02S1
                Funded by: National Center for Advancing Translational Sciences, DOI http://dx.doi.org/10.13039/100006108;
                Funded by: National Institutes of Health, DOI http://dx.doi.org/10.13039/100000002;
                Award ID: UL1 TR001866
                Funded by: Yale Center for Mendelian Genomics;
                Funded by: GSP Coordinating Center;
                Funded by: National Human Genome Research Institute, DOI http://dx.doi.org/10.13039/100000051;
                Award ID: UM1HG006504
                Award ID: U24HG008956
                Funded by: Institut National de la Santé et de la Recherche Médicale, DOI http://dx.doi.org/10.13039/501100001677;
                Funded by: Université de Paris;
                Funded by: UK Research and Innovation Future Leader’s Fellowship;
                Award ID: MR/S032304/1
                Funded by: NIHR Imperial Biomedical Research Centre, DOI http://dx.doi.org/10.13039/501100013342;
                Funded by: Imperial College Healthcare NHS Trust, DOI http://dx.doi.org/10.13039/501100000762;
                Award ID: 70931
                Funded by: Burroughs Wellcome Fund, DOI http://dx.doi.org/10.13039/100000861;
                Funded by: Clinical Immunology Society;
                Funded by: American Academy of Allergy Asthma and Immunology, DOI http://dx.doi.org/10.13039/100002567;
                Funded by: Michael Smith Foundation for Health Research, DOI http://dx.doi.org/10.13039/501100000245;
                Funded by: National Health and Medical Research Council, DOI http://dx.doi.org/10.13039/501100000925;
                Funded by: University of New South Wales, DOI http://dx.doi.org/10.13039/501100001773;
                Funded by: French National Research Agency, DOI http://dx.doi.org/10.13039/501100001665;
                Award ID: ANR-10-IAHU-01
                Award ID: ANR-20-CO11-0001
                Award ID: ANR-10-LABX-62-IBEID
                Funded by: French Foundation for Medical Research;
                Award ID: EQU201903007798
                Funded by: Square Foundation;
                Funded by: Grandir - Fonds de solidarité pour l’enfance;
                Funded by: Fondation du Souffle, DOI http://dx.doi.org/10.13039/100012019;
                Funded by: SCOR Corporate Foundation for Science;
                Categories
                Perspective
                Immunodeficiency
                Covid-19
                Human Disease Genetics
                Innate Immunity and Inflammation

                Medicine
                Medicine

                Comments

                Comment on this article